ZNF469 and neoplasm: Among these, ZNF469 mutations were found to be targeted by neoantigen-specific T-cells in a long-term responder to CIT (44), while ANKRD27 and OTOF were identified as potential tumor-specific antigens for liver and kidney cancer, respectively (45).